Prasinezumab

Pipeline treatments in 7MM prioritize disease-modifying therapies (DMTs) and non-motor symptom therapies for Parkinson’s disease, with 66% of 93 Phase I-III products targeting neuroprotective agents. Key agents include Annovis Bio’s Posiphen and BioVie’s Triolex. Research also focuses on Parkinson’s disease dementia and psychosis, aiming to improve both motor and non-motor symptoms.

Parkinson’s disease (PD) pipeline in 7 major markets emphasizes neuroprotective and disease-modifying therapies (DMTs), with 66% of 93 Phase I-III products targeting mechanisms like alpha-synuclein aggregation. Key opinion leaders (KOLs) support DMT research despite variability in PD pathogenesis, and 18% of the pipeline focuses on non-motor symptoms and postural instability. 3% targets PD-dementia and PD-psychosis, reflecting a comprehensive approach to address both motor and non-motor challenges in PD patients.

MDS 2024 Congress in Philadelphia showcased clinical trials for Parkinson’s disease, including TAK-071 for cognition, subcutaneous carbidopa/levodopa for motor function, adaptive deep brain stimulation (DBS) for patient preference, prasinezumab for motor progression, and NouvNeu001 cell therapy for dopaminergic neuron replacement.

PASADENA and PPMI studies were ethically approved and conducted according to the Declaration of Helsinki and Good Clinical Practice guidelines. PASADENA, a randomized controlled trial, evaluated prasinezumab in early-stage Parkinson’s disease (PD) with 316 participants. PPMI, an observational study, enrolled 397 untreated PD individuals. Data from both studies were used for an exploratory analysis, comparing outcomes between PASADENA groups and the PPMI cohort, focusing on motor progression and other PD-related measures over 4 years.

AbbVie's tavapadon, acquired from Cerevel Therapeutics, significantly reduced Parkinson's disease burden in Phase III TEMPO-1 trial, outperforming placebo in both 5mg and 15mg doses. The drug targets dopamine D1 and D5 receptors, potentially generating $673m by 2030 if approved.

AbbVie’s tavapadon, acquired from Cerevel Therapeutics, significantly reduced Parkinson’s disease burden in Phase III TEMPO-1 trial, outperforming placebo in both 5mg and 15mg doses. The drug also improved motor aspects of daily living and maintained a consistent safety profile. Tavapadon is an oral dopamine receptor agonist targeting D1 and D5 receptors, potentially generating $673m by 2030 if approved.

Federated Hermes Inc. bought 43,861 Prothena Co. plc shares in Q2, valued at $905,000. Other investors also increased holdings, with Artal Group S.A. growing by 99.7% and Wellington Management Group LLP by 21.1%. Prothena's stock opened at $21.61 on Friday, with a market cap of $1.16 billion. The company reported $1.22 EPS for Q2, beating estimates by $2.23. Analysts have a 'Moderate Buy' consensus rating for Prothena, with a price target of $62.86.